Six-month weight loss and comorbidity remission after sleeve gastrectomy, Roux-en-Y gastric bypass, BPD-DS, and SADI-S: propensity score analysis using the 2023 MBSAQIP database.

Raul Sebastian, Oscar Tuesta, Adrian Riva, Alba Zevallos, Gina Adrales, Christina Li, Michael Schweitzer

Abstract read

In one paragraph

Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Raul SebastianDepartment of Surgery, The Johns Hopkins University, Baltimore, MD, USA.

Oscar TuestaDepartment of Surgery, Northwest Hospital, 5401 Old Court Rd., Randallstown, MD, USA. oscar.benari@gmail.com.ORCID http://orcid.org/0000-0003-0309-1246

Adrian RivaDepartment of Surgery, Northwest Hospital, 5401 Old Court Rd., Randallstown, MD, USA.

Alba ZevallosDepartment of Surgery, Loma Linda University Medical Center, Loma Linda, CA, USA.

Gina AdralesDepartment of Surgery, The Johns Hopkins University, Baltimore, MD, USA.

Christina LiDepartment of Surgery, Northwest Hospital, 5401 Old Court Rd., Randallstown, MD, USA.

Michael SchweitzerDepartment of Surgery, The Johns Hopkins University, Baltimore, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBariatric surgery remains the most effective treatment for obesity, yet nationwide bariatric-specific data evaluating early weight loss and comorbidity remission across contemporary procedures are limited. We aimed to compare 6-month outcomes after sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), biliopancreatic diversion with duodenal switch (BPD-DS), and single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S).

methodsWe analyzed adults aged 18-65 years who underwent primary laparoscopic or robotic SG, RYGB, BPD-DS, or SADI-S in the 2023 MBSAQIP database with available long-term follow-up PUF data. Six pairwise 1:1 propensity score-matched analyses were performed using 47 preoperative, intraoperative, and postoperative variables. Outcomes included 6-month weight loss and remission of diabetes, hypertension, hyperlipidemia, sleep apnea, and gastroesophageal reflux disease (GERD).

resultsA total of 116,195 patients were included: 80,614 SG, 33,148 RYGB, 1518 BPD-DS, and 915 SADI-S. Compared with SG, RYGB showed higher remission of diabetes (64.1% vs. 58.1%), hypertension (41.9% vs. 35.8%), hyperlipidemia (43.0% vs. 37.1%), and GERD (55.6% vs. 44.9%), as well as greater %EWL (50.13% vs. 43.63%) (all p < 0.05). Among all procedures, BPD-DS achieved the greatest weight-loss outcomes, with higher %EWL than SG (52.37% vs. 37.73%), RYGB (52.35% vs. 45.92%), and SADI-S (51.07% vs. 45.02%) (all p < 0.05). BPD-DS also showed greater metabolic benefits, including higher diabetes remission than SG (73.3% vs. 59.9%), RYGB (73.1% vs. 65.6%), and SADI-S (77.4% vs. 66.1%), as well as higher hypertension remission than SG (46.0% vs. 31.6%) and RYGB (46.2% vs. 37.6%) (all p < 0.05). Finally, SADI-S showed a similar weight-loss profile to RYGB, with no significant difference in %EWL (44.99% vs. 44.73%, p = 0.126), and comparable remission rates for most evaluated comorbidities.

conclusionIn our national propensity-matched analysis, all evaluated bariatric procedures were associated with significant improvements in weight loss and comorbidity remission. However, RYGB demonstrated higher remission rates than SG, whereas BPD-DS achieved the most favorable 6-month weight-loss and cardiometabolic outcomes among all procedures.

Indexed as

Bariatric surgeryComorbidity remissionDuodenal switchRoux-en-Y gastric bypassSleeve gastrectomyWeight loss

Identifiers

PMID42711587

DOI10.1007/s11695-022-06275-1

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.